Dokument

Summary:
Zoledronic acid is a nitrogen-containing bisphosphonate widely used in the treatment of bone metastasis secondary to breast cancer. In addition, current clinical trials suggest direct antitumor effects, which may reduce the risk of overall disease progression in breast cancer patients. Consistently, recent experimental approaches have demonstrated strong antiproliferative and apoptotic effects in various human cancer cells, although the molecular mechanisms remained elusive. This study was conducted to identify key mechanisms underlying the growth suppressor activity of zoledronic acid in epithelial cancer. For this purpose, we employed an extensive series of cellular, molecular as well as biochemical studies and uncovered the existence of a nuclear GSK3β- NFATc2 stabilization pathway that is target for inactivation by zoledronic acid during growth suppression. GSK3β labels nuclear NFAT through phosphorylation of three phosphoserines (Ser 215, Ser 219 and Ser 223) residues located within the N-terminal SP2 motif of the factor, and this post-translational modification protects the factor from ubiquitination and degradation. The phosphoserine sequences are highly conserved among species and are identical to the previously reported “phospho-degron” elements through which GSK3β labels other key cell cycle regulators for subsequent ubiquitination and proteasomal degradation. Here, we show that GSK3β can make use of the “phospho-degron” elements to stabilize rather than proteolyse mitogenic transcription factors, and thus GSK3β exerts pro-proliferative functions through stabilization of NFATc2 levels in cancer. Treatment with zoledronic acid, however, inhibits GSK3β kinase activity, thus disrupts NFATc2 phosphorylation and stabilization in the nucleus, and finally allows the 26S proteasomal machinery to target NFATc2 for degradation. Mechanistically, HDM2, the human homologue of the E3-ligase MDM2, accumulates in the nucleus upon treatment binds to NFATc2 and transfers ubiquitin to lysines K-684 and K-897. Ubiquitination of K-684 and K-897 requires an unphosphorylated status of NFATc2 in the nucleus and is key for the subsequent recognition and degradation by the 26S proteasome. The net cellular outcome of GSK3β -NFATc2 pathway disruption and degradation of the transcription factor is a progredient halt of cancer cells at the G1 cell cycle phase. Together, this study uncovers a key pathway in cancer growth control that is aimed for inactivation by zoledronic acid. From the medical point of view, we believe that these findings significantly contribute to a better understanding of the biochemical basis underlying one of the most promising and exciting new treatment for malignant disease.

Bibliographie / References

1. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger C, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R, Marth C. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 360: 679- 691.
2. Sasaki A, Boyce BF, Story B. 1995. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55: 3551-3557.
3. Hofbauer LC, Brueck CC, Singh SK, Dobnig H. 2007. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 22: 1317-28 Curriculum Vitae 113 Manuscripts under preparation:
4. Hay RT. 2007. SUMO-specific proteases: a twist in the tail. Trends Cell Biol. References 92
5. Harwood AJ. 2001. Regulation of GSK-3: a cellular multiprocessor. Cell 105: 821–824.
6. Rodriguez MS, Dargemont C, Hay RT. 2001. SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting. J. Biol.
7. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P. 1996. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly. Science. 272: 1023–1026.
8. Seidensticker MJ, Behrens J. 2000. Biochemical interactions in the wnt pathway. Biochim Biophys Acta 495: 168–182. References 98
9. Boyce BF. 1995. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 10: 1478-1487.
10. Muyal JP, Singh SK, Fehrenbach H. 2008. DNA-microarray technology: comparison of methodological factors of recent technique towards gene expression profiling. Crit Rev Biotechnol. 28: 239-51
11. Hall DG, Stoica G. 1994. Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system. J Bone Miner Res. 9: 221-230
12. Stearns ME, Wang M. 1996. Effects of alendronate and taxol on PC-3ML cell bone metastases in SCID mice. Invas Metastasis. 16: 116-131. References 101
13. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C. 2008. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135: 367–375. Abbreviations List of publications
14. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387: 296-9.
15. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P. 2005. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res. 65: 3707–3715.
16. Myeloma interacts with the bone microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 116: 278-290.
17. Rogers MJ. 2003. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Design. 9: 2643–2658.
18. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor supressor p53. FEBS Lett. 420: 25-7.
19. Tilman D. Rachner, Peggy Benad, Martina Rauner, Claudia Goettsch, Singh SK, Michael Schoppet and Lorenz C. Hofbauer. 2009. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem.108: 106-16
20. Pamidronate reduces IL-6 production by bone marrow stroma from muliple myeloma patients. Blood. 88:105.
21. Yu-Cheng S, Geldof AA, Newling DW, Rao BR. 1992. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. J Urol. 148: 1270-1273
22. Erika C. Crouch, Uday Kishore. 2009. Protective effects of recombinant forms of full-length and truncated human surfactant protein D inmurine model of invasive pulmonary aspergilllosis. Mol Immunol. 46: 2363-9.
23. Seufert W, Futcher B, Jentsch S. 1995. Role of a ubiquitin-conjugating enzyme in degradation of S-and M-phase cyclins. Nature. 373: 78-81
24. Henriksen EJ, Dokken BB. 2006. Role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Curr Drug Targets 7: 1435–1441.
25. Shibasaki F, Price ER, Milan D, McKeon F. 1996. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF- AT4 382: 370-3.
26. Hay RT. 2005. SUMO: a history of modification. Mol. Cell 18: 1–12
27. Shipman CM, Croucher PI, Russell RGG, Helfrich MH, Rogers MJ. 1998. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 58: 5294- 5297.
28. Glickman MH, Ciechanover A. 2002. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction. Physiol Rev. 82: 373- 428.
29. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem 67: 425-79.
30. Tilman D. Rachner, Singh SK, Michael Schoppet, Volker Ellenrieder, Regina Ebert, Franz J. Jakob and Lorenz C. Hofbauer. 2009. Zoledronic Acid Induces Apoptosis and Changes the TRAIL/OPG Ratio in Breast Cancer Cells. (In Press in Cancer Letters). Note: Tilman D. Rachner, Singh SK contributed equally.
31. Tonini G. 2003. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 9: 2893-2897.
32. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. 2004. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 10: 4559–4567.
33. Green J, Gschaidmeier H, Yoneda T, Mundy G. 2000. Zoledronic acid potently inhibits tumor-induced osteolysis in two models of breast cancer metastasis to bone. Ann Oncol. 11: 14.
34. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer. 82:1459–1468.
35. Jagdev RE, Coleman CM, Shipman HA, Rostami, Croucher PI. 2001. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 84: 1126–1134.
36. Hofbauer LC, Rachner T, Singh SK. 2008. Fatal attraction: why breast cancer cells home to bone. Breast Cancer Res.10: 101.
37. Ikeda F, Dikic I. 2008. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep. 9: 536–542.
38. Sato M, Grasser W, Endo N. 1991. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88: 2095-2105.

Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten